Bigpharma Partnering Agreements
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Bigpharma – The Top 50
Chapter 3 – Most active bigpharma dealmakers
3.1 Bigpharma M&A activity
3.2 Bigpharma partnering
Chapter 4 – Top bigpharma deals – 2005-7
4.1 Bigpharma M&A
4.2 Bigpharma partnering
Chapter 5 – Bigpharma Agreements
5.1 How to use bigpharma agreements
5.2 What should an agreement contain?
5.3 Deal type definitions
5.4 Company agreement listings
Abbott
Actavis
Akzo Nobel
Allergan
Altana
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Schering Pharma AG
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
King
Lundbeck
Menarini
Merck & Co
Merck – Serono KGaA
Mitsubishi
Novartis AG
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Roche
Sanofi-Aventis
Schering Plough
Serono
Shionogi Seiyaku
Shire
Solvay
Takeda
Tanabe Seiyaku
TAP Pharmaceuticals
Teva
UCB
Watson
Wyeth
Chapter 6 – Resources
Appendices
Appendix 1 – Example development and license contract document
Appendix 2 – Example M&A contract document
About CurrentPartnering
Recent report titles from CurrentPartnering
Figures in report
Figure 1: Bigpharma – top 50 by pharma revenues 2006
Figure 2: Additional bigpharma companies profiled in report
Figure 3: Leading Bigpharma M&A companies, 2006-7
Figure 4: Bigpharma-Bigpharma M&A during 2006-7
Figure 5: Leading Bigpharma partnering companies, 2006-7
Figure 6: Leading M&A deals by value, 2005-7
Figure 7: Leading partnering deals by value, 2005-7
Figure 8: Checklist of key contract agreement clauses in a partnering agreement
Figure 9: Deal type definitions
Figure 10: Online partnering resources
Figure 11: Development and license agreement between Boehringer Ingelheim and
Inspire Pharmaceuticals, February 2006
Figure 12: Agreement and plan of merger between Johnson & Johnson and Guidant
Corporation